Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo (cemiplimab) looks likely to extend its recent run of regulatory approvals as an oncology treatment after the PD-1 inhibitor became the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer.
Positive results from a Phase III trial evaluating Libtayo as a monotherapy for patients whose cervical cancer is recurrent or...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)